Design
CML
CML
A patient-preference trial was performed in order to gain insights into the effectiveness of CMyLife in terms of information provision, patient empowerment, medication compliance, molecular monitoring of BCR-ABL1 values, and quality of life of CML patients. Patients could choose between actively or not actively using CMyLife, including a pre- and post-measurement. The study period lasted from July 2019 to October 2020. Given the nature of this study and the low impact on participants, the Medical Research Involving Human Subjects Act (Dutch: WMO) does not apply, as confirmed by the institutional Medical Ethical Committee ‘CMO Regio Arnhem-Nijmegen’. The trail was registered at ClinicalTrials.gov at 22/10/2020 (registration number: NCT04595955).